The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
Open accessAbstract
Background In cholesterol guidelines, low-density lipoprotein (LDL) cholesterol remains the primary target while apolipoprotein B (apoB) and non-high-density lipoprotein (non-HDL) cholesterol are secondary targets.Objectives This study sought to determine if elevated apoB and/or non-HDL cholesterol are superior to elevated LDL cholesterol in identifying statin-treated patients at residual risk of all-cause mortality and myocardial infarction.Methods In total, 13,015 statin-treated patients from the Copenhagen General Population Study were included with 8 years median follow-up. Cox regressions among apoB, non-HDL cholesterol, and LDL cholesterol, respectively, and all-cause mortality or myocardial infarction were examined on continuous scales by restricted cubic splines and by categories of concordant and discordant values defined by medians.Results High apoB and non-HDL cholesterol were associated with increased risk of all-cause mortality and myocardial infarction, whereas no such associations were found for high LDL cholesterol. Compared with concordant values below medians, discordant apoB above the median with LDL cholesterol below yielded hazard ratios of 1.21 (95% confidence interval [CI]: 1.07 to 1.36) for all-cause mortality and 1.49 (95% CI: 1.15 to 1.92) for myocardial infarction. Corresponding values for high non-HDL cholesterol with low LDL cholesterol were 1.18 (95% CI: 1.02 to 1.36) and 1.78 (95% CI: 1.35 to 2.34). In contrast, discordant high LDL cholesterol with low apoB or non-HDL cholesterol was not associated with increased risk of all-cause mortality or myocardial infarction. Also, discordant high apoB with low non-HDL cholesterol yielded hazard ratios of 1.21 (95% CI: 1.03 to 1.41) for all-cause mortality and of 0.93 (95% CI: 0.62 to 1.40) for myocardial infarction. Furthermore, dual discordant apoB and non-HDL cholesterol above the medians with LDL cholesterol below presented hazard ratios of 1.23 (95% CI: 1.07 to 1.43) for all-cause mortality and 1.82 (95% CI: 1.37 to 2.42) for myocardial infarction.Conclusions In statin-treated patients, elevated apoB and non-HDL cholesterol, but not LDL cholesterol, are associated with residual risk of all-cause mortality and myocardial infarction. Discordance analysis demonstrates that apoB is a more accurate marker of all-cause mortality risk in statin-treated patients than LDL cholesterol or non-HDL cholesterol, and apoB in addition is a more accurate marker of risk of myocardial infarction than LDL cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“T2D dyslipidemia is characterized by increased levels of triglyceriderich lipoproteins (VLDL), intermediate-density lipoprotein, and remnant particlesdall apo Becontaining particlesd which metabolically lead to low levels of HDL-C and increased levels of small, dense LDL-C.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [310]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, apoB was identified as a more accurate marker for the risk of myocardial infarction than LDL cholesterol [42].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“given that apoB is a more accurate measure of the adequacy of lipid-lowering therapy than LDL-C or non-HDL-C,1,3–13,27”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, all reports since then, with one exception,2 including observational studies and randomized clinical trials,3–13 have confirmed that apoB is a more accurate marker of cardiovascular risk than LDL-C or non-HDL-C, reinforcing the validity of the evaluation by the 2019 EAS/ESC Guidelines as to the superiority of apoB.”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This study builds on prior work showing that apoB concentration is the most predictive parameter of CV risk,13,14,15”
From Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Johannesen et al. conducted a study which revealed that in patients undergoing statin treatment, elevated levels of apolipoprotein B (apoB) and non-HDL cholesterol, rather than LDL cholesterol, are correlated with residual risk of all-cause mortality and myocardial infarction.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“Their discordance analysis indicated that apoB serves as a more precise marker of all-cause mortality risk in statin-treated patients compared to LDL cholesterol or non-HDL cholesterol.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [42]
The cited source says what the claim attributes to it.
In the citing paper
“This is particularly relevant given the growing body of evidence indicating that non–HDL cholesterol and ApoB are important predictors of ASCVD risk [38, 39].”
From The Efficacy and Safety of Plozasiran on Lipid Profile in Dyslipidemic Disorders: A Systematic Review and Meta-Analysis (2026) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Self-citationGenetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Self-citationNordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw152 · Cited by 847
Self-citationBoekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A. D., Furberg, C. D., KEECH, A. C., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 449
Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 429
Mora, S., Buring, J. E., & Ridker, P. M. (2014) · Circulation · doi:10.1161/circulationaha.113.005873 · Cited by 255
Sniderman, A. D., St-Pierre, A. C., Cantin, B., Dagenais, G. R., Després, J.-P., & Lamarche, B. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00262-5 · Cited by 224
A Test in Context: Lipid Profile, Fasting Versus Nonfasting
Nordestgaard, B. G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.006 · Cited by 223
Self-citationRidker, P. M., Mora, S., & Rose, L. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw046 · Cited by 222
Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.234146 · Cited by 209
Self-citationResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 174
Pencina, M. J., D’Agostino, R. B., Zdrojewski, T., Williams, K., Thanassoulis, G., Furberg, C. D., Peterson, E. D., Vasan, R. S., & Sniderman, A. D. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315569411 · Cited by 164
Thanassoulis, G., Williams, K., Ye, K., Brook, R., Couture, P., Lawler, P. R., de Graaf, J., Furberg, C. D., & Sniderman, A. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000759 · Cited by 148
Sniderman, A. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.006 · Cited by 116
Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB
Sniderman, A. D., Lamarche, B., Contois, J. H., & Graaf, J. D. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000127 · Cited by 76
Soran, H., Schofield, J. D., Adam, S., & Durrington, P. N. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000318 · Cited by 49
Flagged first, then by citations
Cited by
Sorted by citations
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Metadata
- Authors
- Johannesen, C. D. L., Mortensen, M. B., Langsted, A., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Nordestgaard, Børge Grønne
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 77
- Issue
- 11
- Pages
- 1439-1450
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3139070968
- Semantic Scholar
- c048cafbb84a1b51c0efb41514223f4c3011f674
- Cited by
- 359
- References
- 26
- Citations by year
- 2026: 72 · 2025: 62 · 2024: 76 · 2023: 77 · 2022: 43 · 2021: 27
- FWCI
- 52.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Gentofte Hospital
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein B, non-HDL cholesterol, LDL cholesterol, residual cardiovascular risk, statin-treated patients, all-cause mortality, myocardial infarction, lipid targets, cardiovascular risk prediction, Copenhagen General Population Study, secondary prevention of cardiovascular disease, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, hyperhomocysteinemia
- MeSH terms
- Heart Disease Risk Factors, Aged, Apolipoproteins B, Denmark, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Mortality, Myocardial Infarction, Registries, Biomarkers, Causality, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
